Received Jul 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
patient who got 1st dose in May 2021, then 2nd dose in Oct 2023; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose in May 2021). In OCT-2023, the patient received the 2nd dose of Shingrix. In OCT-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient who got 1st dose in May 2021, then 2nd dose in Oct 2023). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 24-APR-2024 The reporter reported that the patient who got 1st dose in May 2021, then 2nd dose in October 2023. The patient thought that she needed to get a new series, but registered pharmacist did not think she needed one. The patient received the 2nd dose of Twinrix later than the recommended interval, which led to lengthening of vaccine schedule.